Lilly, other drugmakers itching to find new psoriasis treatment

Back to TopCommentsE-mailPrintBookmark and Share

Psoriasis, with its patches of itchy, flaky skin, is often nothing more than a benign cosmetic problem. Yet, for many people, it’s as disabling and threatening as rheumatoid arthritis or cancer.

These patients often don’t tolerate existing medicines, or see them lose their power over time. Pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., have a new understanding of the biology behind the disease and are developing a new class of drug candidates that may be faster and more effective for the more serious forms of psoriasis.

The front runner, Novartis AG, said Thursday that its experimental treatment met the main goals of a late-stage study.

Psoriasis is linked to higher rates of heart disease and diabetes, and a third of patients also develop a form of arthritis, which causes pain and swelling in and around the joints, said Kristian Reich, a dermatologist in Hamburg who also teaches at the University of Goettingen.

“This is a really serious inflammatory illness, like rheumatoid arthritis, except that it doesn’t affect the joints, it affects the skin,” said Reich, who has tested the Novartis drug and two others in clinical trials.

It’s impossible to gauge the full toll of psoriasis on people’s lives. In addition to the physical pain and danger of complications are the psychological wounds.

“These people don’t get the jobs they should be getting,” Reich said. “They don’t marry the partners they should be marrying.”

About 125 million people worldwide have the skin condition, including 7.5 million Americans, according to the National Psoriasis Foundation. About 20 percent to 30 percent of them have a moderate to serious form of the disease, of which half are taking some kind of medicine, said John Hohneker, who heads drug development for autoimmune diseases at Basel, Switzerland-based Novartis.

“We know that 40 to 50 percent are dissatisfied with their current therapy,” Hohneker said.

Novartis’s therapy, secukinumab, worked “significantly” better than Amgen Inc.’s Enbrel, the $3.7 billion-a-year drug that is considered the standard of care, in clearing the skin in a late-stage study, the company said in a prepared statement. The research is being presented at the European Academy of Dermatology and Venereology meeting in Istanbul, which began Oct. 2.

Lilly and a partnership of Amgen and AstraZeneca Plc are also working on new medicines. Lilly said it expects late-stage results next year.

Brodalumab, the drug from Thousand Oaks, Calif.-based Amgen and AstraZeneca of London, is also in late-stage testing. At the conference, the companies will present results from the second of three phases of human testing usually required by regulators.

Older therapies block a chemical called TNF, which is produced by the immune system and causes inflammation in the body. TNF blockers are used against a variety of autoimmune diseases, including rheumatoid arthritis.

The new drugs block IL-17, a protein involved in sending signals in the immune system. Psoriasis occurs when the immune system over-reacts to cuts or scrapes, leading to an abnormally rapid buildup of skin cells. Scientists found the points of attack through better understanding of the protein.

Because the new psoriasis drugs target IL-17, they may have fewer side effects than older medicines, start working faster and require fewer injections, according to Andrea Chiricozzi, a dermatologist at the University of Rome who has studied the biology of the disease.

“For these agents, the efficacy is very good, and there are no major concerns about safety,” Chiricozzi said. Side effects in clinical trials have included common colds, upper respiratory tract infections and injection-site reactions.

People who have psoriasis usually try a range of both over- the-counter and prescription creams before starting to take methotrexate, a cheap generic drug, treatments that may not be sufficient for patients with a more severe form of the disease.

Then they move to injectable therapies such as Enbrel from Amgen, or Humira from North Chicago, Illinois-based AbbVie Inc. Both Enbrel and Humira are TNF blockers and are used to treat rheumatoid arthritis, which like psoriasis is an autoimmune disease. Patients may also take Johnson & Johnson’s Stelara, a drug approved to treat psoriasis. Stelara targets IL-12 and IL-23, two other proteins that play a role in the immune system’s responses.

The TNF blockers don’t help every patient and may become less effective over time, said Lawrence Green, a dermatologist in the Washington, D.C., area and chairman of the National Psoriasis Foundation’s research committee.

If drugmakers succeed in winning approval for the new medicines, the products have the potential to expand the psoriasis market from the $5 billion now spent on expensive biological therapies to $8 billion by 2017, according to Andrew Baum, a pharmaceutical-industry analyst at Citigroup Inc.

The drugs in development are better at clearing the skin than older therapies, according to Citi’s Baum. In mid-stage clinical trials, the experimental medicines were deemed effective in about 80 percent of patients, compared with 49 percent for Enbrel and 75 percent for Humira.

“Patients want to have normal lives,” Novartis’s Hohneker said.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. I think the poster was being sarcastic and only posting or making fun of what is usually posted on here about anything being built in BR or d'town for that matter.

  2. Great news IRL fans: TURBO the IMS sanctioned movie about slugs running the Indy 500 has caught the Securities and Exchange Commission because Dreamworks had to take a $132MILLION write down...because the movie was such a flop. See, the Indy/IMS magic soiled another pair of drawers. Bwahahahahahaha! How's CARTOWN doing? HAHAHAHA...Indy is for losers.

  3. So disappointed in WIBC. This is the last straw to lose a good local morning program. I used to be able to rely on WIBC to give me good local information, news, weather and traffic on my 45 minute commute.Two incidents when I needed local, accurate information regarding severe weather were the first signs I could not now rely on WIBC. I work weekend 12 hour nights for a downtown hospital. This past winter when we had the worst snowfall in my 50 years of life, I came home on a Sunday morning, went to sleep (because I was to go back in Sunday night for another 12 hour shift), and woke up around 1 p.m. to a house with no electricity. I keep an old battery powered radio around and turned on WIBC to see what was going on with the winter storm and the roads and the power outage. Sigh. Only policital stuff. Not even a break in to update on the winter storm warning. The second weather incident occurred when I was driving home during a severe thunderstorm a few months ago. I had already gotten a call from my husband that a tornado warning was just southwest of where I had been. I turned to WIBC to find out what direction the storm was headed so I could figure out a route home, only to find Rush on the air, and again, no breaking away from this stupidity to give me information. Thank God for my phone, which gave me the warning that I was driving in an area where a tornado was seen. Thanks for nothing WIBC. Good luck to you, Steve! We need more of you and not the politics of hatred that WIBC wants to shove at us. Good thing I have Satellite radio.

  4. I read the retail roundup article and tried Burritos and Beers tonight. I'm glad I did, for the food was great. Fresh authentic Mexican food. Great seasoning on the carne asada. A must try!!! Thanks for sharing.

  5. John, unfortunately CTRWD wants to put the tank(s) right next to a nature preserve and at the southern entrance to Carmel off of Keystone. Not exactly the kind of message you want to send to residents and visitors (come see our tanks as you enter our city and we build stuff in nature preserves...